Business
Jim Lang Elected to Halozyme's Board of Directors
SAN DIEGO, Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (\"Halozyme\") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of executive leadership experience in healthcare, life sciences, business services and data analytics.\"Jim brings extensive experience in building and scaling innovative healthcare businesses, and we are delighted to welcome him to the Halozyme board,\" said Dr. Helen Torley, president and chief executive officer. \"His strategic insight and proven ability to drive growth, including through M&A, will be a tremendous asset as we deliver on our growth strategy and create meaningful new value for our stakeholder, including partners, patients, and shareholders.\"Most recently, Mr. Lang served as Chief Executive Officer of EVERSANA, building the leading global provider of commercialization services to the life sciences industry. As CEO, Mr. Lang led the company's growth through the acquisition of over twenty companies, culminating in its merger with Waltz Health in August 2025. Mr. Lang remains on EVERSANA's board. He also formerly served as CEO of Decision Resources Group (DRG), where he transformed DRG into a leading healthcare data and analytics firm through significant expansion and acquisitions. Previously, Mr. Lang was President of Strategic Decision Group, where he expanded the life sciences practice and later sold it to IMS Health (now IQVIA).Mr. Lang currently serves on the board of Biovie, Inc., a clinical-stage biopharmaceutical company, where he chairs both the Audit Committee and the Nominating and Corporate Governance Committee. He also serves on the board of OptimizeRx Corporation, a digital healthcare technology company, acting as chair of the Compensation Committee and as a member of the Nominating and Corporate Governance Committee.\"I am honored to join Halozyme's Board of Directors,\" said Mr. Lang. \"Halozyme has a strong foundation and a compelling strategy for growth. I look forward to working with the leadership team to help accelerate that growth and deliver even greater value to our shareholders.\"Mr. Lang earned his B.S. in in Electrical and Computer Engineering from the University of New Hampshire and his MBA from the Tuck School of Business at Dartmouth.About HalozymeHalozyme is a biopharmaceutical company ...